1-7 of 7
Zisong Zhou
Close
Sort by
Journal Articles

Safety and Efficacy of Relmacabtagene Autoleucel (relma-cel) in Adults with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL): Updated Results from a Phase II Open-Label Study in China

Yuqin Song, Keshu Zhou, Lanfang Li, Aibin Liang, Yun Qin, Zhen Xia, Yongen Gu, Zisong Zhou, Alex Tian, Jun Zhu
Journal: Blood
Blood (2023) 142 (Supplement 1): 3024.
https://doi.org/10.1182/blood-2023-178430
Published: 2023
Journal Articles

Preliminary Safety and Efficacy of Relmacabtagene Autoleucel (relma-cel) in Adults with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL) in China

Zhitao Ying, Keshu Zhou, Lanfang Li, Wenyu Li, Su Yang, Yun Liu, Yongen Gu, Zisong Zhou, Alex Tian, Yuqin Song, Jun Zhu
Journal: Blood
Blood (2022) 140 (Supplement 1): 7470–7471.
https://doi.org/10.1182/blood-2022-164525
Published: 2022
Journal Articles

Efficacy and Safety of Relmacabtagene Autoleucel in Adults with Relapsed/Refractory Follicular Lymphoma in China

Yuqin Song, Zhitao Ying, Haiyan Yang, Ye Guo, Wenyu Li, Dehui Zou, Jianqiu Wu, Alex Tian, Tony Huang, Zisong Zhou, Meilin Ma, Su Yang, Yun Qin, Jun Zhu
Journal: Blood
Blood (2022) 140 (Supplement 1): 10329–10331.
https://doi.org/10.1182/blood-2022-162985
Published: 2022
Journal Articles

Primary Clinical Response of Relmacabtagene Autoleucel in Adults with Relapsed/Refractory Follicular Lymphoma (r/r FL) in China

Yuqin Song, Zhitao Ying, Haiyan Yang, Ye Guo, Wenyu Li, Dehui Zou, Jianqiu Wu, Su Yang, Pian Zhang, Meilin Ma, Zisong Zhou, Hongxia Zheng, Jun Zhu
Journal: Blood
Blood (2021) 138 (Supplement 1): 2434.
https://doi.org/10.1182/blood-2021-150085
Published: 2021
Journal Articles

Relmacabtagene Autoleucel CD19 CART Therapy for Adults with Heavily-Pretreated Relapsed/Refractory Large B-Cell Lymphoma in China

Yuqin Song, Zhitao Ying, Haiyan Yang, Ye Guo, Wenyu Li, Dehui Zou, Daobin Zhou, Zhao Wang, Mingzhi Zhang, Jianqiu Wu, Hui Liu, Pian Zhang, Su Yang, Zisong Zhou, Hongxia Zheng, Jun Zhu
Journal: Blood
Blood (2021) 138 (Supplement 1): 3557.
https://doi.org/10.1182/blood-2021-148358
Published: 2021
Journal Articles

Clinical Response of CD19 CAR-T Cells (relmacabtagene autoleucel, relma-cel) in Adults with Heavily-Pre-Treated Relapsed/Refractory (r/r) Large B-Cell Lymphoma in China

Jun Zhu, MD, Zhitao Ying, MD, Yuqin Song, MD PhD, Haiyan Yang, MD PhD, Ye Guo, MD, Wenyu Li, PhD, Dehui Zou, MD, Daobin Zhou, MD PhD, Zhao Wang, MD, Mingzhi Zhang, MD, Jianqiu Wu, MD, Hui Liu, MD, Pian Zhang, Su Yang, Zisong Zhou, Hongxia Zheng, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 39–40.
https://doi.org/10.1182/blood-2020-136038
Published: 2020
Journal Articles

Cellular Kinetics and Anti-Therapeutic Antibody in Relapsed/Refractory B-NHL Patients Treated with JWCAR029

Zhitao Ying, MD PhD, Pengpeng Xu, MD, Ming Hao, PhD, Li Wang, MD PhD, Shu Cheng, MD PhD, Wen Wu, MD PhD, Wen Wang, MD PhD, Zisong Zhou, Su Yang, Jennifer Wang, PhD, Harry Lam, PhD, James Li, Hongxia Zheng, MD PhD, Weili Zhao, MD PhD, Yuqin Song, MD PhD, Jun Zhu, BS
Journal: Blood
Blood (2019) 134 (Supplement_1): 4083.
https://doi.org/10.1182/blood-2019-126408
Published: 2019